+086 1911-7288-062 [ CN ]
Cookies give you a personalized experience,Сookie files help us to enhance your experience using our website, simplify navigation, keep our website safe and assist in our marketing efforts. By clicking "Accept", you agree to the storing of cookies on your device for these purposes.For more information, review our Cookies Policy.
Share:
Novonesis A/S (Lyngby, Denmark) has signed an agreement with the intent to acquire MicroBioGen Pty Ltd (Sydney, Australia), an Australian biotechnology company with leading scientific expertise in yeast strains for industrial applications, particularly in bioethanol.
The acquisition builds on Novonesis’ 2013 investment in MicroBioGen and its current 23% stake, further strengthening a decade-long collaboration in cutting-edge yeast solutions to bioethanol production.
Ester Baiget, CEO: “This acquisition marks an additional measure in our 2030 strategy. It strengthens our yeast capabilities, strengthens our R&D capabilities, and reflects our disciplined investment focus to drive development.”
Building on deep scientific expertise
As a pure-play biology company, Novonesis combines deep scientific expertise in microbiology and manufacturing fermentation with approximately 10% of annual sales investment in innovation. The acquisition of MicroBioGen builds on this foundation, strengthening core expertise in biological solutions.
“We see MicroBioGen as a perfect match building on greater than a decade of close collaboration, and we look forward to integrating their methodology into Novonesis. With the acquisition, we will continue to enhance our capabilities and develop the biosolutions our customers need,” said Claus Crone Fuglsang, Chief Scientific Officer, Novonesis.
As part of the agreement, Novonesis will continue to support MicroBioGen’s existing partners and ensure continuity in its collaborations.
Geoffrey Bell, CEO and co-founder of MicroBioGen, said: “Joining Novonesis is a strong fit to MicroBioGen and its employees. After greater than a decade of close collaboration, we could not think of a better home to the company.”
The terms of the transaction will not be disclosed, and completion of the transaction is subject to customary regulatory approvals, including by the ACCC (Australia’s national competition, consumer, fair trading, and product security regulator).
We will contact you soon
888CHEM
Japanese 
Korean 
Hindi 
Russian 
Arabic 
Malay 
